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Background: to compare the effect of valsartan (Val) or ramipril (Ram) addition to amlodipine (Aml)/hydrochlorotiazide(HCTZ) combination on 
left ventricular (LV) mass in type 2 diabetic hypertensive patients with LV hypertrophy. 
Methods: a total of 180 mild to moderate hypertensive outpatients with well controlled type 2 diabetes and LV hypertrophy after a 2 week 
placebo period were treated with Aml 10 mg/HCTZ 12.5 mg for 4 weeks: the 154 patients whose blood pressure BP was not normalized by the 
dual combination (SBP > 130 mmHg and/or DBP > 80 mmHg) were enrolled in the study and randomized to the addition of valsartan 320 mg 
or ramipril 10 mg for 12 months. At the third month the non responder patients were discontinued. A total of 142 patients completed the study. 
Echocardiographic evaluation was performed at the end of the placebo period, of the amlodipine/HCTZ period and after 12 months of triple 
combination treatment. 
Results: systolic and diastolic BP were similarly and significantly reduced in both treatment groups (-9.2 ± 5.5/-6.9 ± 3.4 mmHg in the valsartan 
group; -9.1 ± 5.9/-6.7 ± 3.8 in the ramipril group; all p<0.01 vs Aml/HCTZ combination). LV mass index was reduced significantly in both treatment 
groups (-9.6 ± 3.6 g/m2 in the valsartan group and -7.1 ± 3.1 g/m2 in the ramipril group; p<0.001 vs amlodipine/HCTZ combination), however the 
reduction was significantly greater with valsartan than with ramipril (p<0.01). Safety and tolerability were similar across both treatment groups. 
Conclusions: Val/Aml/HCTZ combination was effective in promoving LV mass regression, and such regression was significantly greater than that 
obtained with Ram/Aml/HCTZ, independent of BP lowering. This finding suggests that valsartan is more effective than ramipril in attenuating this 
measure of myocardial damage in diabetic hypertensive patients with LV hypertrophy.
